Prospective study on the effect of apixaban on vascular endothelial functio
- Conditions
- non-valvular atrial fibrillation patientsI480
- Registration Number
- JPRN-jRCTs031180347
- Lead Sponsor
- Adachi Taro
- Brief Summary
Oral apixaban was found to improve vascular endothelial function in patients with non-valvular atrial fibrillation, and it was thought that a decrease in inflammatory cytokines was involved in the reason, but in this study, it was not a significant change.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Subjects are 50 patients that consecutive cases of eligible non valvular atrial fibrillation patients (at least 15 paroxysmal atrial fibrillation cases and at least 15 sustained atrial fibrillation case). Also, more than 5 subjects with 2 CHADS scores and more than 5 subjects with 3 or more CHADS2 scores are entered respectively.
1) Patients contraindicated for anticoagulant drug
2) Patients complicated of malignant tumor
3) Patients who judged ineligible from the examining physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method vascular endothelial function
- Secondary Outcome Measures
Name Time Method ab test (general peripheral blood. total protein, albumin, CK, Cr, AST, ALT, gannma GTP, TG, LDL, HDL, oxidant LDL, hs TNF-arfa, IL-6, Adiponectin, Thrombomodulin, hs CRP, ADMA, Insulin, fibrinogen, D-dimer, TAT, PIC, F1 plus 2, PAI-1, BNP,general urine